Cell News and Research

RSS

Researchers study incidence of heterosis for different characteristics

When two gene pools combine, you might expect the characteristics of the offspring to end up somewhere in the middle between those of its parents. But children often have characteristics that are better or worse than that middle value, sometimes even better than both parents.

9 Dec 2009

First-quarter fiscal 2010 results announced by Helix BioPharma

Helix BioPharma Corp. today announced financial results for the first quarter ended October 31, 2009.

9 Dec 2009

Severe pandemic scenario can impact blood supplies

A German research team has examined data on supply and demand for blood transfusions against a computer simulation of an influenza pandemic, and discovered that a severe pandemic scenario could quickly lead to a deficit of up to 96,000 red blood cell (RBC) transfusion units in Germany alone, creating potentially fatal outcomes. Their study is published today in the journal TRANSFUSION.

9 Dec 2009

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

Lung cancer is the leading cause of cancer mortality worldwide and lung adenocarcinoma is the most common type. Many cases of lung adenocarcinoma are attributed to a mutation in a gene for the epidermal growth factor receptor (EGFR).

9 Dec 2009

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

9 Dec 2009

TMZ and small molecule combination appears to lower tumor resistance

University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells.

9 Dec 2009

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

9 Dec 2009

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.

9 Dec 2009

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.

9 Dec 2009

Progenitor-cell therapy can reduce risk of another heart attack

Cells from heart attack survivors' own bone marrow reduced the risk of death or another heart attack when they were infused into the affected artery after successful stent placement, according to research reported in the American Heart Association journal Circulation: Heart Failure.

9 Dec 2009

Multi-institutional study identifies potential treatment target for ovarian cancer

A multi-institutional study has identified a potential personalized treatment target for the most common form of ovarian cancer. In the December 8 issue of Cancer Cell, the research team describes finding that a gene called MAGP2 - not previously associated with any type of cancer - was overexpressed in papillary serous ovarian tumors of patients who died more quickly. They also found evidence suggesting possible mechanisms by which MAGP2 may promote tumor growth.

9 Dec 2009

Xanthohumol compound may aid in preventing prostate cancer

The natural compound xanthohumol blocks the effects of the male hormone testosterone, therefore aiding in the prevention of prostate cancer.

9 Dec 2009

Immune-boosting drug: A new way for improving cancer treatment

Stimulating the body's own immune system to fight cancer offers new treatment opportunities for cancer patients, and scientists have made the first step towards finding existing drugs that could help.

9 Dec 2009

New breakthrough study shows reconstruction of human mandible bone with dental stem cells

In a statement today, StemSave(TM), Inc., the market leader in the field of stem cell recovery and cryo-preservation lauds research published in the November issue of the European Cells and Materials Journal citing the reconstruction of the human mandible bone with autologous dental pulp stem cells.

9 Dec 2009

Bird influenza viruses have a variety of strategies to cross the species barrier

The 2009 H1N1 influenza virus used a new strategy to cross from birds into humans, a warning that it has more than one trick up its sleeve to jump the species barrier and become virulent.

9 Dec 2009

Combination of gene and cell therapy improves critical limb ischemia associated with aging or diabetes

Blood vessel blockage, a common condition in old age or diabetes, leads to low blood flow and results in low oxygen, which can kill cells and tissues. Such blockages can require amputation resulting in loss of limbs. Now, using mice as their model, researchers at Johns Hopkins have developed therapies that increase blood flow, improve movement and decrease tissue death and the need for amputation.

8 Dec 2009

MCG receives $1.8M stimulus grant

It's a $1.8 million shot in the arm to the largest grant the Medical College of Georgia has ever received.

8 Dec 2009

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company’s oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.

8 Dec 2009

RIVA System effective in automatically compounding IV doses in syringes with minimal contamination

A recent study demonstrated the RIVA System (Robotic Intravenous Automation) - a self-contained unit for aseptic compounding from Intelligent Hospital Systems (IH Systems) - is an effective tool in automatically compounding IV doses in syringes and bags with minimal drug contamination.

8 Dec 2009

Micromet presents final data from its blinatumomab Phase 2 study for ALL

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL).

8 Dec 2009

Cell News and Research

Researchers study incidence of heterosis for different characteristics

First-quarter fiscal 2010 results announced by Helix BioPharma

Severe pandemic scenario can impact blood supplies

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

TMZ and small molecule combination appears to lower tumor resistance

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

Progenitor-cell therapy can reduce risk of another heart attack

Multi-institutional study identifies potential treatment target for ovarian cancer

Xanthohumol compound may aid in preventing prostate cancer

Immune-boosting drug: A new way for improving cancer treatment

New breakthrough study shows reconstruction of human mandible bone with dental stem cells

Bird influenza viruses have a variety of strategies to cross the species barrier

Combination of gene and cell therapy improves critical limb ischemia associated with aging or diabetes

MCG receives $1.8M stimulus grant

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

RIVA System effective in automatically compounding IV doses in syringes with minimal contamination

Micromet presents final data from its blinatumomab Phase 2 study for ALL

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News